Cardioxyl Pharmaceuticals

Bristol-Myers Squibb to acquire Cardioxyl

Monday, November 2, 2015

Bristol-Myers Squibb will acquire all of the issued and outstanding capital stock of Chapel Hill, N.C.-based Cardioxyl Pharmaceuticals, a private biotechnology company focused on cardiovascular disease. The acquisition will give Bristol-Myers Squibb full rights to Cardioxyl’s lead asset CXL-1427, a novel nitroxyl (HNO) donor (prodrug) in phase II clinical development as an intravenous treatment for acute decompensated heart failure (ADHF).

[Read More]